Seattle Genetics Inc. (NASDAQ:SGEN) was up 2.4% on Friday . The stock traded as high as $43.27 and last traded at $43.01, with a volume of 284,202 shares trading hands. The stock had previously closed at $42.01.

Several equities research analysts have recently weighed in on SGEN shares. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price objective (up from $60.00) on shares of Seattle Genetics in a research report on Wednesday, June 29th. Vetr cut Seattle Genetics from a “strong-buy” rating to a “hold” rating and set a $36.00 price objective for the company. in a research report on Wednesday, April 6th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Seattle Genetics in a research report on Monday, June 20th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $43.00 target price on shares of Seattle Genetics in a research report on Wednesday, June 8th. Finally, Zacks Investment Research raised Seattle Genetics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the company’s stock. Seattle Genetics currently has an average rating of “Buy” and an average price target of $46.61.

The firm’s 50 day moving average price is $40.43 and its 200 day moving average price is $36.49. The firm’s market capitalization is $6.02 billion.

Seattle Genetics (NASDAQ:SGEN) last posted its earnings results on Thursday, April 28th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.06. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. The company earned $111.15 million during the quarter, compared to analyst estimates of $116.49 million. The company’s revenue was up 35.3% compared to the same quarter last year. Equities research analysts predict that Seattle Genetics Inc. will post ($1.10) EPS for the current year.

In other Seattle Genetics news, CEO Clay B. Siegall sold 7,618 shares of the company’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $35.16, for a total value of $267,848.88. Following the transaction, the chief executive officer now directly owns 563,733 shares of the company’s stock, valued at approximately $19,820,852.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Clay B. Siegall sold 22,083 shares of the company’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $43.59, for a total value of $962,597.97. Following the completion of the transaction, the chief executive officer now directly owns 566,538 shares in the company, valued at $24,695,391.42. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Eagle Asset Management raised its position in shares of Seattle Genetics by 53.2% in the third quarter. Eagle Asset Management now owns 594,490 shares of the company’s stock worth $22,922,000 after buying an additional 206,317 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Seattle Genetics by 12.7% in the fourth quarter. New York State Common Retirement Fund now owns 388,566 shares of the company’s stock worth $17,439,000 after buying an additional 43,913 shares in the last quarter. California Public Employees Retirement System raised its position in shares of Seattle Genetics by 14.0% in the fourth quarter. California Public Employees Retirement System now owns 294,700 shares of the company’s stock worth $13,226,000 after buying an additional 36,300 shares in the last quarter. Commerzbank Aktiengesellschaft FI raised its position in shares of Seattle Genetics by 274.9% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 25,323 shares of the company’s stock worth $1,136,000 after buying an additional 18,569 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in shares of Seattle Genetics by 16.8% in the fourth quarter. ProShare Advisors LLC now owns 116,188 shares of the company’s stock worth $5,215,000 after buying an additional 16,725 shares in the last quarter.

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.